- Home
- NMG vs ZURA Comparison
NMG vs ZURA Comparison
Compare NMG & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NMG | ZURA |
|---|---|---|
| Founded | 2011 | 2022 |
| Country | Canada | United States |
| Employees | N/A | 40 |
| Industry | Other Metals and Minerals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.9M | 455.4M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | NMG | ZURA |
|---|---|---|
| Price | $1.27 | $5.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $5.75 | ★ $13.00 |
| AVG Volume (30 Days) | 581.0K | ★ 1.5M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.28 | $1.35 |
| 52 Week High | $6.06 | $7.25 |
Technical Indicators
Market Signals| Indicator | NMG | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 29.29 | 52.35 |
| Support Level | N/A | $5.17 |
| Resistance Level | $1.67 | $5.88 |
| Average True Range (ATR) | 0.09 | 0.40 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 1.43 | 40.12 |
Price Performance
Historical ComparisonAbout NMG Nouveau Monde Graphite Inc.
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The Company currently operates in two segments: the Mining projects (which includes the Matawinie Mine project and the Uatnan Mining Project) and the Battery Material Plant project.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.